TKI discontinuation safe in CML, improved PROs
November 12, 2020
Brian Druker, M.D., and Ted Braun, M.D., Ph.D., co-author an invited commentary in JAMA Oncology on the “consequential” patient-reported outcomes found in a clinical trial studying chronic myeloid leukemia patients who remained in treatment-free remission after tyrosine kinase inhibition treatment discontinuation. “These findings provide objective evidence that important measures of quality of life do improve off therapy.”